Prostaglandins and Their Synthesis Inhibitors in Cancer

  • Alan Bennett
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 54)


The relationships of prostaglandins (PGs) to cancer have been reviewed recently [1, 2], so that this chapter deals mainly with a brief outline of previous work, and fuller accounts of the latest findings.


Synthesis Inhibitor Human Lung Cancer Prostaglandin Synthesis Inhibitor Estrogen Receptor Content Plasma Protein Binding Site 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. Bennett, Prostaglandins and cancer, in: “Practical Applications of Prostaglandins and Their Synthesis Inhibitors,”(S. M. M. Karim, ed.), MTP Press, Lancaster, p. 149 (1979).Google Scholar
  2. 2.
    A. Bennett, Prostaglandins and inhibitors of their synthesis in cancer growth and spread, in: “Endocrinology of Cancer;” Vol. 3,(D. P. Rose, ed), C. R. C. Press, Inc., Florida, Chapter 6, in press.Google Scholar
  3. 3.
    E. F. Voelkel, A. H. Tashjian, R. Franklin, E. Wasserman, and L. Levine, Hypercalcemia and tumor prostaglandins: the VX2 carcinoma model in the rabbit, Metabolism, 24:973 (1975).PubMedCrossRefGoogle Scholar
  4. 4.
    A. H. Tashjian, E. F. Voelkel, and L. Levine, Plasma concentrations of 13, 14-dihydro-15-keto-prostaglandin E2 in rabbits bearing the VX2 carcinoma: effects of hydrocortisone and indomethacin, Prostaglandins, 14:309 (1977).PubMedCrossRefGoogle Scholar
  5. 5.
    H. W. Seyberth, W. C. Hubbard, 0. Oelz, B. J. Sweetman, J. T. Watson, and J. A. Oates, Prostaglandin mediated hypercalcemia in the VX2 carcinoma-bearing rabbit, Prostaglandins, 14:1125 (1977).CrossRefGoogle Scholar
  6. 6.
    L. Levine, Levels of 13,14-dihydro-l5-keto-PGE2 in some biological fluids as measured by radioimmunoassay, Prostaglandins, 14:1125 (1977).PubMedCrossRefGoogle Scholar
  7. 7.
    R. Mortel, J. C. Allegra, L. M. Demers, H. A. Harvey, J. Trautlein, W. Nahhas, D. White, M. A. Gillin, and A. Lipton, Plasma prostaglandins across the tumor bed of patients with gynecologic malignancy, Cancer, 39:2201 (1977).PubMedCrossRefGoogle Scholar
  8. 8.
    I. F. Stamford, J. Maclntyre, and A. Bennett, Human breast carcinomas release prostaglandin-like material into the blood, in: “Advances in Prostaglandin and Thromboxane Research,” Vol. 6,(B. Samuelsson, P. W. Ramwell, and R. Paoletti, eds), Raven Press, New York, p. 571 (1980).Google Scholar
  9. 9.
    J. F. Caro, A. Besarab, and J. T. Flynn, Prostaglandin E and hypercalcemia in breast carcinoma: Only a tumor marker? Amer. J. Med., 66:337 (1979).Google Scholar
  10. 10.
    L. M. Demers, J. Schweitzer, A. Lipton, and H. Harvey, Blood 6-keto-PGFla levels as potential tumor marker, Cancer Treat. Rep., 63:1210 (1979).Google Scholar
  11. 11.
    O. Khan, C. N. Hensby, and G. Williams, Prostacyclin in prostatic cancer, in: “Clinical Pharmacology of Prostacyclin,” Chapter 7,(P. J. Lewis and J. O’Grady, eds), Raven Press, New York (1981).Google Scholar
  12. 12.
    P. Hilgard and R. D. Thornes, Anticoagulants in the treatment of cancer, Eur. J. Cancer., 22:755 (1976).Google Scholar
  13. 13.
    N. S. B. Tanner, I. F. Stamford, and A. Bennett, Plasma prostaglandins in mucositis due to radiotherapy and chemotherapy, Br. J. Cancer, 43:767 (1981).PubMedCrossRefGoogle Scholar
  14. 14.
    A. Bennett, E. M. Charlier, A. M. McDonald, J. S. Simpson, I. F. Stamford, and T. Zebro, Prostaglandins and breast cancer, Lancet, 2:624 (1977).PubMedCrossRefGoogle Scholar
  15. 15.
    P. H. Rolland, P. M. Martin, J. Jacquemier, A. M. Rolland, and M. Toga, Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells, J. Natl. Cancer Inst., 64:1061 (1980).PubMedGoogle Scholar
  16. 16.
    A. Bennett, D. A. Berstock, B. Raja, and I. F. Stamford, Survival time after surgery is inversely related to the amounts of prostaglandins extracted from human breast cancers, Br. J. Pharmacol., 66:451P (1979a).Google Scholar
  17. 17.
    A. J. Wilson, M. Baum, A. Bennett, K. Griffiths, R. I. Nicholson, and I. F. Stamford, Lymph node status, prostaglandins and estrogen receptors are independent prognostic variables in human primary breast cancer, Clin. Oncol., 6:379 (1980).Google Scholar
  18. 18.
    W. E. Kibbey, D. G. Bronn, and J. P. Minton, Prostaglandins and metastasis, Lancet, 1:101 (1978).PubMedCrossRefGoogle Scholar
  19. 19.
    A. Bennett, M. A. Carroll, I. F. Stamford, W. F. Whimster, F. Williams, and J. E. Wright, Prostaglandins and human lung cancer, Br. J. Pharmac., 74:207P (1981b).Google Scholar
  20. 20.
    I. F. Stamford, A. Bennett, M. A. Carroll, C. N. Hensby, W. F. Whimster, and F. Williams, Human lung cancer and prostaglandins, in: “Prostaglandins and Cancer,”(T. J. Powles, ed.), Alan R. Liss, Inc., New York, in press.Google Scholar
  21. 21.
    C. Favalli, E. Garaci, E. Etheredge, M. G. Santoro, and B. M. Jaffe, Influence of PGE on the immune response in melanoma-bearing mice, J. Immunol., 125:897 (1980).PubMedGoogle Scholar
  22. 22.
    D. Hofer, A. M. Dubitsky, P. Reilly, M. G. Santoro, and B. M. Jaffe, The interactions between indomethacin and cytotoxic drugs in mice bearing B-16 melanomas. Prostaglandins, 20:1033 (1980).PubMedCrossRefGoogle Scholar
  23. 23.
    J. P. Kelly, M. C. Johnson, and C. W. Parker, Effect of inhibitors of arachidonic acid metabolism on mitogenesis in human lymphocytes: possible role of thromboxanes and products of lipoxygenase pathway, J. Immunol., 122:1563 (1979).PubMedGoogle Scholar
  24. 24.
    G. A. Higgs, K. E. Eakins, K. G. Mugridge, S. Moncada, and J. R. Vane, The effect of non-steroid anti-inflammatory drugs on leukocyte migration in carrageenin-induced inflammation, Eur. J. Pharmacol., 66:81 (1980).PubMedCrossRefGoogle Scholar
  25. 25.
    P. J. M. Tutton and D. H. Barkla, Influence of prostaglandin analogues on epithelial cell proliferation and xenograft growth, Br. J. Cancer, 41:47 (1980).PubMedCrossRefGoogle Scholar
  26. 26.
    N. R. Lynch, M. Castes, M. Astonin, and J. C. Salomon, Mechanism of inhibition of tumor growth by aspirin and indomethacin, Br. J. Cancer, 38:503 (1978).PubMedCrossRefGoogle Scholar
  27. 27.
    A. Bennett, J. Houghton, D. J. Leaper, and I. F. Stamford, Cancer growth, response to treatment and survival time in mice: beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen, Prostaglandins, 17:179 (1979b).CrossRefGoogle Scholar
  28. 28.
    O. J. Plescia, A. H. Smith, and K. Grinwich, Subversion of immune system by tumor cells and role of prostaglandins, Proc. Natl. Acad. Sci., USA, 72:1848 (1975).PubMedCrossRefGoogle Scholar
  29. 29.
    C. B. Anderson, R. J. Graff, and B. M. Jaffe, Prostaglandin E prolongation of murine skin allografts, Surg. Formum, 27:330 (1976).Google Scholar
  30. 30.
    H. B. Hewitt, E. R. Blake, and A. S. Walder, A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumors of spontaneous origin, Br. J. Cancer, 33:241 (1976).PubMedCrossRefGoogle Scholar
  31. 31.
    D. J. Leaper, B. T. French, and A. Bennett, Breast cancer and prostaglandins: a new approach to treatment, Br. J. Surg., 66:683 (1979).PubMedCrossRefGoogle Scholar
  32. 32.
    M. A. Bach and J. F. Bach, Studies on thymus products, IV. The effects of cyclic nucleotides and prostaglandins on rosette-forming cells. Interactions with thymic factor, Eur. J. Immunol., 3:778 (1973).PubMedCrossRefGoogle Scholar
  33. 33.
    L. D. Loose and N. R. DiLuzio, Effect of prostaglandin E1 on cellular and humoral immune responses, J. Reticuloendothelial Soc., 13:70 (1973).Google Scholar
  34. 34.
    M. G. Santoro, G. W. Philpott, and B. M. Jaffe, Inhibition of tumor growth in vivo and in vitro by prostaglandin E. Nature, 263:777 (1976).CrossRefGoogle Scholar
  35. 35.
    R. T. Prehn, The immune reaction as a stimulator of tumor growth, Science, 176:170 (1972).PubMedCrossRefGoogle Scholar
  36. 36.
    E. Razin and A. Globerson, The effect of various prostaglandins on plasma membrane receptors and function of mouse macrophages, Adv. Exp. Med. Biol., 114:415 (1979).PubMedGoogle Scholar
  37. 37.
    R. L. Oropeza-Rendon, V. Speth, G. Hiller, K. Weber, and H. Fischer, Prostaglandin E1 reversibly induces morphological changes in macrophages and inhibits phagocytosis. Experimental Cell Research, 119:365 (1979).PubMedCrossRefGoogle Scholar
  38. 38.
    G. J. Gasic, T. B. Gasic, N. Galanti, T. Johnson, and S. Murphy, Platelet tumor-cell interactions in mice. The role of platelets in the spread of malignant disease, Int. J. Cancer, 11: 704 (1973).PubMedCrossRefGoogle Scholar
  39. 39.
    A. Bennett, D. A. Berstock, and M. A. Carroll, Enhanced anticancer effect by combining cytotoxic drugs with the prostaglandin synthesis inhibitor flurbiprofen, Br. J. Pharmac., 71: 208P (1981a).Google Scholar
  40. 40.
    S. Wood and P. Hilgard, Aspirin and tumor metastasis, Lancet, 2:1416 (1972).PubMedCrossRefGoogle Scholar
  41. 41.
    T. J. Powles, S. A. Clark, D. M. Easty, G. C. Easty, and A. M. Neville, The inhibition by aspirin and indomethacin of osteolytic tumour deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer, Br. J. Cancer, 28:316 (1973).PubMedCrossRefGoogle Scholar
  42. 42.
    C. S. B. Galasko and A. Bennett, Relationshp of bone destruction in the development of skeletal metastases to osteoclast activation and prostaglandins, Nature, 263:508 (1976).PubMedCrossRefGoogle Scholar
  43. 43.
    A. Robert, Cytoprotection by prostaglandins, Gastroenterology, 77:761 (1979).PubMedGoogle Scholar
  44. 44.
    T.J. Powles, P. Alexander, and J. L. Millar, Enhancement of anti-cancer activity of cytotoxic chemotherapy with protection of normal tissues by inhibition of prostaglandin synthesis, Biochem. Pharmacol., 27:1389 (1978).Google Scholar
  45. 45.
    T. J. Powles and J. L. Millar, Non-steroidal anti-inflammatory drugs and cytotoxics, Cancer Treat. Rev., 6 (Suppl.), 63 (1979).PubMedCrossRefGoogle Scholar
  46. 46.
    S. A. T. Mennie, V. Dalley, L. C. Dinneen, and H. O. J. Collier, Treatment of radiation-induced gastrointestinal distress with acetylsalicylate, Lancet, 2:942 (1975).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1983

Authors and Affiliations

  • Alan Bennett
    • 1
  1. 1.Department of SurgeryKing’s College Hospital Medical SchoolLondonEngland

Personalised recommendations